


Curriculum Vitae

Name	Changhoon Yoo	
Current Position & Affiliation	Associate Professor, Asan Medical Center, University of Ulsan College of Medicine	
Country	Korea	

Educational Background

2000. 3 – 2006. 2	M.D.	Graduate summa cum laude University of Ulsan College of Medicine Seoul, Korea
2009. 3 – 2011.2	Master of Science	Postgraduate School University of Ulsan College of Medicine Seoul, Korea
2015. 3 – 2019.2	Ph.D.	Postgraduate School University of Ulsan College of Medicine Seoul, Korea

Professional Experience

2006. 3 – 2007. 2	Internship	Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea
2007. 3 – 2011. 2	Residency, Internal Medicine	Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea
2014. 5 – 2016. 2	Clinical fellow, Medical Oncology	Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2016. 3 – 2021.02	Assistant Professor, Medical Oncology	Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2021. 3 – Associate Professor, Medical Oncology Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Professional Organizations

Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Society of Medical Oncology
Member, Korean Cancer Association
Member, American Society of Clinical Oncology
Member, European Society of Medical Oncology
Member, Korean Liver Cancer Association

Main Scientific Publications

Yoo C, Lee SS, Song KB, Jeong JH, Hyung J, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Lee SS, Kim JH, Jin HS, Park JH, Hwang DW, Lee JH, Lee W, Chang HM, Kim KP, Ryoo BY, Kim SC. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. *Br J Cancer*. 2020;123:362-8.

Chae H, Kim D, **Yoo C***, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. *Eur J Cancer*. 2019 Aug 30;120:31-39. doi: 10.1016/j.ejca.2019.07.022.

Yoo C*, Hwang I, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Lee SK, Kim MH, Byun JH, Park JH, Hwang DW, Song KW, Lee JH, Lee W, Chang HM, Kim KP, Kim SC, Ryoo BY. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. *Ther Adv Med Oncol*. 2020 <https://doi.org/10.1177/1758835920953294>

Kang JH, Lee SS, Kim JH, Byun JH, Kim HJ, **Yoo C**, Kim KP, Ryoo BY, Kim SC. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. *Eur Radiol*. 2020 Aug 19. doi: 10.1007/s00330-020-07134-8. Online ahead of print.